Global HIV funding drops 25% in 2025
Analysis based on 6 articles · First reported Jul 28, 2026 · Last updated Jul 30, 2026
The funding decline threatens the continuity of HIV treatment and prevention programs, potentially increasing infections and deaths, which could raise healthcare costs and reduce productivity in affected regions. Pharmaceutical companies supplying antiretroviral drugs may face reduced demand from donor-funded programs, while domestic market growth in some countries could partially offset losses.
International donor funding for HIV programs fell by 25% in 2025, the steepest annual decline since global HIV financing began, according to reports by UNAIDS and KFF released at the 26th International AIDS Conference in Rio de Janeiro. The reduction, driven almost entirely by a sharp decrease in United States funding due to delays and cancellations of global health projects, cut donor disbursements to US$6.2 billion from US$8.3 billion in 2024, the lowest level since 2007. Domestic HIV financing rose by 4% and now accounts for nearly 60% of total funding, but UNAIDS warned this is insufficient to offset the international shortfall. An estimated 1.2 million people acquired HIV in 2025 and 570,000 died from AIDS-related illnesses, leaving the world off track to end AIDS by 2030. New infections are rising in Brazil, Pakistan, the Philippines, and Madagascar, while Kenya, Lesotho, Rwanda, Zimbabwe, and Eswatini continue to make progress. UNAIDS Executive Director Winnie Byanyima called for urgent debt restructuring and increased domestic investment, while WHO Director-General Tedros Adhanom Ghebreyesus warned that gains remain fragile without sustained commitment. The conference, organized by the International AIDS Society, runs from July 26 to 31 and has brought together about 7,000 participants.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard